Abattis Bioceuticals Corp
Abattis Bioceuticals Corp. operates as a life sciences and biotechnology company in Canada. The company develops and licenses natural health products, medicines, extractions, and ingredients for the biological, nutraceutical, bioceutical, and cosmetic markets. It also provides Comfort, a cannabinoid enhanced nutraceutical for pain and inflammation; and Health-Canada licensed services for the cann… Read more
Abattis Bioceuticals Corp (ATTBF) - Total Liabilities
Latest total liabilities as of September 2019: $8.59 Million USD
Based on the latest financial reports, Abattis Bioceuticals Corp (ATTBF) has total liabilities worth $8.59 Million USD as of September 2019.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Abattis Bioceuticals Corp - Total Liabilities Trend (2008–2019)
This chart illustrates how Abattis Bioceuticals Corp's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Abattis Bioceuticals Corp Competitors by Total Liabilities
The table below lists competitors of Abattis Bioceuticals Corp ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Uravi Defence and Technology Limited
NSE:URAVIDEF
|
India | ₹333.61 Million |
|
Green Giant Inc.
NASDAQ:GGEI
|
USA | $194.69 Million |
|
Nextgen
TA:NXGN
|
Israel | ILA11.20 Million |
|
Nabors Energy Transition Corp. II Warrant
NASDAQ:NETDW
|
USA | $14.15 Million |
Liability Composition Analysis (2008–2019)
This chart breaks down Abattis Bioceuticals Corp's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.73 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.78 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.45 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Abattis Bioceuticals Corp's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Abattis Bioceuticals Corp (2008–2019)
The table below shows the annual total liabilities of Abattis Bioceuticals Corp from 2008 to 2019.
| Year | Total Liabilities | Change |
|---|---|---|
| 2019-09-30 | $8.59 Million | +2734.79% |
| 2018-09-30 | $303.16K | -31.00% |
| 2017-09-30 | $439.38K | -58.46% |
| 2016-09-30 | $1.06 Million | -6.97% |
| 2015-09-30 | $1.14 Million | -9.82% |
| 2014-09-30 | $1.26 Million | +17.68% |
| 2013-09-30 | $1.07 Million | +52.71% |
| 2012-09-30 | $701.56K | +450.41% |
| 2011-09-30 | $127.46K | -70.54% |
| 2010-09-30 | $432.60K | +158.55% |
| 2009-09-30 | $167.32K | +200.28% |
| 2008-09-30 | $55.72K | -- |